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ABSTRACT
Introduction. Telcagepant (MK-0974) is a novel, orally active and selective CGRP receptor antagonist being
investigated for acute treatment of migraine. Early clinical data suggested greater than dose proportional increases
in exposure following oral administration. The aim of the present studies was to deﬁnitively characterize the oral and
IV dose proportionality of telcagepant.
Methods. Healthy adult subjects were enrolled in two separate open-label randomized dose proportionality studies:
1) single oral dose crossover from 50 to 600 mg (N = 19); 2) single IV dose parallel group from 5 to 250 mg (N = 10
per dose). Blood samples were collected at time points from 0 to 48 hours postdose.
Results. Telcagepant was rapidly absorbed with a Tmax of approximately 1 to 2 hours after oral administration. The
terminal half-life was approximately 8 to 9 hours after IV dosing and approximately 4 to 7 hours after oral dosing.
Oral administration of telcagepant resulted in greater than dose proportional increases in exposure, while IV
administration resulted in approximately dose proportional increases in exposure.
Conclusions. Telcagepant was generally well tolerated. Oral telcagepant exhibits non-linear pharmacokinetics.
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Introduction
M
igraine is a common disease and a leading
cause of disability [1]. In the United States,
work loss due to migraine is estimated to cost
$13 billion [2]. Calcitonin gene-related peptide
(CGRP) is a neuropeptide that may play a key
role in the pathophysiology of migraine [3,4].
Since CGRP receptor antagonists lack direct
vasoconstrictor activity, this new mechanism of
action may offer advantages over current triptan
treatments, where cardiovascular liabilities are a
major perceived risk [5], or may offer another
treatment option in patients who do not respond
to triptans.
Telcagepant (formerly known as MK-0974) is
an orally available, selective and potent antagonist
of the human CGRP receptor [6–8]. Telcagepant
is currently in development for the acute treat-
ment of migraine, and may have the potential to
treat migraineurs with cardiovascular disease. The
efﬁcacy and tolerability of telcagepant has been
demonstrated in phase 3 clinical trials at doses of
150 and 300 mg [9,10].
Non-clinical assessments of telcagepant in
monkeys and rats suggested species dependent
non-linear pharmacokinetics following oral doses
of telcagepant. Intestinal ﬁrst-pass metabolism was
concluded to play a signiﬁcant role [11]. A similar
observation was made in early clinical studies [12]
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in exposure following oral administration were
apparent. Here, the dose proportionality of tel-
cagepant is formally characterized in a deﬁnitive
oral dose proportionality study and compared to
the results from a second study in which the dose
proportionality following IV administration of
telcagepant was characterized.
Material and Methods
Study Design
Two single-center, open-label, randomized studies
were performed. The oral dosing study (Merck
Protocol 029) was a 5-period crossover design with
doses of 50, 150, 300, 450 and 600 mg. The IV
study (Merck Protocol 019) was a 7-panel parallel
design with doses of 5, 10, 25, 50, 100, 175, and
250 mg; the study used a parallel design because of
dosing limitations imposed by the inclusion of
Captisol® in the IV formulation (possible renal
toxicity). The oral study was conducted at CPI
Comprehensive Neuroscience, Inc., Miramar, FL,
USA and the IV study was conducted at CEDRA
Clinical Research, Austin, TX, USA. The studies
were performed in conformance with legal
requirements for the ethical conduct of research in
human subjects and were approved by Indepen-
dent Investigational Review Board, Inc., Planta-
tion, FL (oral study) and IntegReview Ethical
Review Board, Austin, TX (IV study). All subjects
gave written informed consent.
Patients
Both studies enrolled healthy, non-smoking adult
male and female subjects. Subjects were required
to have a body mass index 33 kg/m
2 (oral study)
or 35 kg/m
2 (IV study), and females were
required to have a negative pregnancy test at
screening and agree to remain abstinent or use
appropriate double barrier contraception during
the study. The oral study enrolled 20 subjects; 14
males ages 25 to 55 years, and 6 females, ages 39 to
43 years. One subject who completed the study
but took concomitant medication was excluded
from the pharmacokinetic analysis. The IV study
enrolled 70 subjects (10 per dose group); 36 males
ages 18–44 years and 34 females ages 19–43 years.
Drug Supplies
Oral telcagepant was supplied in soft gelatin
(oral soft elastic) capsules manufactured by
Banner Pharmacaps, Inc. The bulk drug used was
telcagepant, monopotassium salt, ethanolate,
supplied by Merck Research Laboratories. The
IV formulation of telcagepant consisted of
telcagepant, monopotassium salt, ethanolate
infused as a 6 mg/mL solution (containing 35%
Captisol®).
Study Procedures
Both studies were performed in specialist clinical
research units. Concomitant medication was pro-
hibited from 48 hours before dosing. For the oral
5-period, crossover study, the order in which
the subjects received each dose was randomized
according to a computer generated allocation
schedule. Each subject received each dose with
240 mL of water at the same time in each period,
after an overnight 8-hour fast. There was at least a
7-day washout interval between each treatment
period. For the IV study, the treatment group to
which subjects were assigned (10 per group) was
enrolled sequentially. The study started with the
lowest dose group (5 mg) and subsequent groups
were dosed incrementally (10, 25, 50, 100, 175,
and 250 mg) dependent on the tolerability and
pharmacokinetic proﬁle observed in the previous
group. For each subject, after an overnight fast, the
appropriate volume of IV solution was withdrawn
from pre-ﬁlled vials and then infused via infusion
tubing. Doses were administered at a constant rate
of 20 minutes via a syringe-type, rate-controlled,
infusion pump. In both studies, plasma samples
were collected at predose and at speciﬁed time
points up to 48 hours following dosing and subject
safety was monitored by repeated clinical and
laboratory evaluations, including assessment of
adverse events.
Bioanalysis
Plasma samples were analyzed for telcagepant con-
centrations; details of the bioanalytical methods
are published elsewhere [13]. Both analyte and
internal standard were isolated from human
plasma using solid phase extraction in 96-well
format. The extracted analytes were analyzed by
high performance liquid chromatography with
tandem mass spectrometry. The lower limit of
quantitation for telcagepant was 5 nM. The linear
calibration curve range was 5 to 5000 nM.
Pharmacokinetic and Statistical Methods
The (apparent) terminal rate coefﬁcient (l) was
estimated by regression of the terminal log-linear
portion of the plasma concentration-time proﬁle.
The (apparent) terminal half-life was calculated as
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plasma concentration versus time curve to the last
time point (AUClast) was calculated using the linear
trapezoidal method for ascending concentra-
tions and the logarithmic trapezoidal method for
descending concentrations. The area under the
plasma concentration versus time curve (AUC0-•)
was estimated as the sum of AUClast and the quo-
tient of the last measured concentration and l.
The maximum concentration observed (Cmax) and
the time in which Cmax was observed (Tmax) were
assessed by inspection of the plasma concentration
data. For the intravenous study, the actual volume
of telcagepant delivered was estimated from the
difference in mass of the ﬁlled syringe, before and
after telcagepant administration. The clearance
was calculated as the quotient of the dose and
AUC0-•. The volume of distribution at steady-
state was calculated as the product of the clear-
ance and mean residence time at steady-state.
WinNonlin (Pharsight) 5.0.1 was used for all
pharmacokinetic calculations.
For the oral study, the primary assessment of
dose proportionality for telcagepant AUC0-• was
performed using the power model, as deﬁned on
the log scale below, in which m is the overall mean,
b is the overall slope, Sj is the random effect of
subject j and e is the random error:
ln AUC S ln dose j jj () =++ ( )+ μβ ε
The slope (b) was estimated using a mixed-
effects model with dose as a ﬁxed effect and with
subject as a random effect. The slope was esti-
mated with an appropriately chosen contrast. On
the original scale, the power model is expressed as
AUC =a j(dose)
b, with aj = exp(m+Sj +e j). Under
this model, exact dose-proportionality is present
when the true value of b=1. The degree of dose
proportionality over the dose range was estimated
by calculating the 90% conﬁdence interval for
the slope.
To better illustrate the effect of the estimated
slope, the true increase in AUC0-• resulting from a
12-fold increase in dose (i.e., over the entire dose
range studied) was estimated using the relationship
AUC600-mg/AUC50-mg = 12
b, where b was the slope
estimated from the power model. The 90% con-
ﬁdence interval for this ratio was also calculated by
substituting the lower and upper bound of the
90% conﬁdence interval computed for the slope
into the relationship above. Based on the observed
data, the method to estimate dose proportionality
over the entire range was successively applied to
smaller segments (50–450 mg, 50–300 mg) to esti-
mate dose proportionality over other ranges of
interest.
Similar analytic methods were used to analyze
data from the IV study. Due to the parallel group
design, the random effect of subject j was not
included in the power model. To better illustrate
theeffectoftheestimatedslope,thetrueincreasein
AUC0-• resulting from a 50-fold increase in dose
(i.e., over the entire dose range studied) was esti-
mated using the relationship AUC250-mg/AUC5-mg
= 50
b, where b was the slope estimated from
the power model. The 90% conﬁdence interval for
this ratio was also calculated by substituting the
lower and upper bound of the 90% conﬁdence
interval computed for the slope into the relation-
ship above.
Results
Single Oral Dose Pharmacokinetics
Telcagepant was rapidly absorbed with median
time to peak plasma concentration (Tmax) ranging
from 1 to 2 hours (Table 1). Telcagepant concen-
trations declined from the peak plasma concentra-
tion (Cmax) in a biphasic manner (Figure 1) with an
apparent terminal half-life (t1/2) of approximately
4 to 7 hours (Table 1). Tmax was similar across
doses. The apparent terminal half-life appeared to
Table 1 Summary of telcagepant plasma pharmacokinetics following single oral doses in healthy adult subjects (N = 19)
Dose
(mg)
AUC0-• AUC0-4h Cmax Tmax t1/2
(mM·h) (mM·h) (mM) (h) (h)
GM
CV
(%) GM
CV
(%) GM
CV
(%) Median (Min, Max) HM
Pseudo
SD
50 1.38 44 0.94 45 0.57 45 1.00 (0.50, 1.50) 4.1 1.6
150 5.05 49 3.21 51 1.60 55 1.50 (0.50, 1.50) 6.8 2.6
300 14.03 49 8.31 50 3.89 53 1.50 (1.00, 3.00) 6.5 1.5
450 25.04 41 13.93 38 5.75 37 1.50 (1.00, 3.00) 6.9 2.6
600 48.71 38 23.52 32 9.04 30 2.00 (1.00, 4.00) 6.8 2.2
GM = Model based geometric mean; Min = Observed minimum; Max = Observed maximum; HM = Harmonic mean; SD = Standard deviation; CV = Coefficient of
Variation.
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founded by the inadequate characterization of the
terminal phase at lower doses because the concen-
tration fell below the lower limit of quantiﬁcation.
Table 2 contains point estimates and 90%
conﬁdence intervals for the slopes from the power
model used to assess dose proportionality of tel-
cagepant AUC0-•, AUC0-4h and Cmax over the dose
ranges of interest. Greater than dose proportional
increases were observed in the area under the
concentration-time curve estimated to inﬁnity
(AUC0-•) and estimated to 4 hours post dose
(AUC0-4h) over the range of 50 to 600 mg, 50 to
450 mg, and 50 to 300 mg. While the increase in
AUC were greater than dose proportional over
all ranges evaluated, Cmax was greater than dose-
proportional over the range of telcagepant 50
to 600 mg, but approximately dose-proportional
over the ranges of 50 to 300 mg and 50 to 450 mg.
The estimated regression line and corresponding
95% conﬁdence band are displayed graphically in
Figure 2 for AUC0-•.
Single IV Dose Pharmacokinetics
The pharmacokinetics of telcagepant after single
IV dose administration of telcagepant to healthy
subjects were evaluated over the dose range of
5 mg to 250 mg (Table 3). Following single IV
doses, telcagepant exhibited a multiphasic plasma
concentration-time proﬁle (Figure 3). The termi-
nal half-life appeared to increase with dose and
plateau near the apparent terminal half-life
Figure 1 Mean telcagepant plasma
concentrations versus time following
single oral doses of 50 mg to 600 mg
in healthy adult subjects (inset:
semilog scale) (N = 19). Time (hr)
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Table 2 Dose proportionality of telcagepant following single oral doses in healthy adult subjects (N = 19)
Pharmacokinetic
Parameter
No. of
Doses
Low
Dose
(mg)
High
Dose
(mg)
Estimated Slope
†
(90% CI)
Predicted Fold-
Change (90% CI)
Expected Fold-Change
with Perfect Dose
Proportionality MSE*
AUC0-• (mM·h) 5 50 600 1.40 (1.35, 1.46) 32.6 (28.5, 37.2) 12.0 0.0785
4 50 450 1.32 (1.26, 1.38) 18.2 (15.8, 20.9) 9.0
3 50 300 1.28 (1.20, 1.37) 10.0 (8.6, 11.6) 6.0
AUC0-4h (mM·h) 5 50 600 1.28 (1.22, 1.34) 24.0 (20.7, 27.8) 12.0 0.0953
4 50 450 1.23 (1.16, 1.30) 14.9 (12.7, 17.4) 9.0
3 50 300 1.21 (1.11, 1.30) 8.7 (7.4, 10.2) 6.0
Cmax (mM) 5 50 600 1.11 (1.05, 1.17) 15.7 (13.5, 18.2) 12.0 0.0968
4 50 450 1.07 (1.00, 1.14) 10.5 (9.0, 12.3) 9.0
3 50 300 1.06 (0.97, 1.16) 6.7 (5.7, 8.0) 6.0
*Mean square error on log-scale.
†Exact dose proportionality present when true slope is equal to 1.
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low half-life estimates from lower doses may not
represent the terminal half-life as the concentra-
tion of telcagepant was near or below the lower
limit of quantitation at those doses. A minor
decrease in the clearance was noted with increas-
ing doses, and the volume of distribution increased
with dose, though these changes may reﬂect inac-
curacies in the estimation of the terminal phase at
the lower doses due to concentrations being below
the lower limit of quantitation.
Table 4 contains point estimates and 90%
conﬁdence intervals for the slopes from the power
model used to assess dose proportionality of tel-
cagepant AUC0-•, AUC0-4h and Cmax over the 5 mg
to 250 mg dose range. Following administration of
a single IV dose of telcagepant, an approximately
dose-proportional increase in AUC0-•, AUC0-4h,
and Ceoi was observed. The estimated regression
line and corresponding 95% conﬁdence band are
displayed graphically in Figure 4 for AUC0-•.
Safety andTolerability
Telcagepant was generally well tolerated in both
studies. No serious clinical or laboratory adverse
experience were reported and no subject discon-
tinued because of an adverse experience. There
were no consistent treatment-related changes in
laboratory, vital sign, or ECG parameters.
In the oral study, all clinical adverse experiences
were mild and resolved. A total of 16 clinical
adverse experiences were reported by 4 out of 20
subjects; 1 during a period in which the subject
received a single dose of 150 mg, 6 during periods
in which subjects received a single dose of 300 mg,
100
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Arch Drug Info 2010;3:55–627 during periods in which subjects received a
single dose of 450 mg, and 2 during periods in
which subjects received a single dose of 600 mg.
Those clinical adverse experiences which occurred
more than once were constipation, upper respira-
tory tract infection (one was considered viral),
headache, dizziness and nausea.
In the IV study, a total of 29 out of 70 subjects
reported 47 adverse experiences. Of the 47 adverse
experiences, 17 occurred prior to dosing and 30
occurred on-treatment. Twenty-ﬁve of the 47 total
reported adverse experiences were related to
the IV infusion (e.g., infusion pain). Among the
12 clinical adverse experiences which were
on-treatment and were not related to the IV infu-
sion, those which occurred more than once were
headache and dizziness.
Discussion
In the ﬁeld of migraine therapy, where most
medication is self-administered by patients, the
availability of an oral formulation is particularly
important. Telcagepant is a novel, orally active and
selective CGRP receptor antagonist being devel-
oped for the acute treatment of migraine. Tel-
cagepant, at doses of 150 and 300 mg of the oral
soft elastic liquid ﬁlled capsule formulation, dem-
onstrated efﬁcacy superior to placebo in human
clinical studies [9,10]. The studies described here
were conducted to understand the relationship
between dose and plasma exposures following
single oral doses of telcagepant capsules ranging
from 50 mg to 600 mg and single IV doses of tel-
cagepant capsules from 5 to 250 mg.
Following oral administration, telcagepant is
rapidly absorbed with a median Tmax o f1t o2
hours and an apparent terminal half-life of 4 to
7 hours [12]. Early clinical studies suggested
greater than dose proportional increases in expo-
sure following oral administration, which may
indicate changes in clearance or bioavailability
[12]. In non-clinical studies, oral dosing of tel-
cagepant in rhesus monkeys was observed to result
Figure 3 Mean telcagepant plasma
concentrations versus time following
single IV doses of 5 mg to 250 mg in
healthy adult subjects (inset: semilog
scale) (N = 10 per dose). Time (hr)
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Table 4 Dose proportionality of telcagepant following single IV doses of 5 to 250 mg in healthy adult subjects (N = 10
per dose
†)
Pharmacokinetic
Parameter
Estimated Slope
‡
(90% CI)
Predicted Fold-
Change (90% CI)
Expected Fold-Change
with Perfect Dose
Proportionality MSE*
AUC0-• (mM·h) 1.07 (1.03, 1.11) 66.4 (56.5, 78.0) 50.0 0.078
AUC0-4h (mM·h) 1.04 (1.00, 1.07) 57.7 (49.7, 67.0) 50.0 0.067
Ceoi (mM) 1.00 (0.95, 1.05) 50.2 (41.8, 60.4) 50.0 0.103
*Mean Square error on log-scale.
†For Ceoi at 50 mg IV dose, N = 9. Ceoi value for one subject excluded from analysis due to incorrrect infusion time.
‡Exact dose proportionality present when true slope is equal to 1.
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in exposure. The non-linear pharmacokinetics of
telcagepant in rhesus monkeys was attributed to
intestinal ﬁrst-pass metabolism [11]. The initial
clinical observations in the context of the non-
clinical results prompted the present formal evalu-
ation of the dose proportionality in a deﬁnitive
oral dose proportionality clinical study and in an
IV dose proportionality clinical study.
In the present study, the pharmacokinetics
of telcagepant following oral administration to
healthy adult subjects were non-linear with greater
than dose proportional increases in AUC0-• and
AUC0-4h over all ranges evaluated while Cmax was
greater than dose proportional over the range of
50 to 600 mg. Cmax was approximately dose pro-
portional over the ranges of 50 to 300 mg and 50
to 450 mg. The possibility that the non-linear
oral pharmacokinetics observed in healthy adult
subjects were due to interactions at the gastroin-
testinal level was evaluated by comparing these
ﬁndings with the dose proportionality of tel-
cagepant following single IV doses.
Following IV administration, approximately
dose proportional increases in AUC0-•, AUC0-4h,
and Ceoi were observed with minimal change in
the clearance. The terminal half-life appeared to
increase with dose, and plateau near the apparent
terminal half-life estimate for an oral dose of
300 mg; however, because the concentration of
telcagepant was near or below the lower limit
of quantitation at lower doses, it is unclear whether
this trend is solely due to the pharmacokinetics of
telcagepant. Instead, it is likely that the half-life
estimates at lower doses do not represent the ter-
minal half-life. A minor decrease in the clearance
was observed with increasing doses while the
volume of distribution increased with dose. These
results suggest that the changes in distribution and
elimination are minor, and these changes may not
be meaningful in the context of dose proportion-
ality. It is important to understand that due to
safety limitations of an excipient in the IV formu-
lation, it was not possible to dose subjects more
than once (as in a cross-over study). Therefore,
this study used parallel panels of subjects to con-
struct the dose escalation, though it is expected
that this design does not impact the conclusions
to a meaningful extent.
Telcagepant is metabolized via CYP3A4 and is a
substrate of P-glycoprotein in addition to being a
time dependent inhibitor of CYP3A4. Both of
these proteins are likely to play an important role
in the bioavailability of telcagepant and the activity
of each protein in the gut wall is theoretically
saturable at clinically achievable drug concentra-
tions. Thus, data from the oral dose proportional-
ity study, data from the IV dose proportionality
study, and knowledge of the molecular determi-
nants of the disposition of telcagepant, are con-
sistent with the possibility that greater than dose
proportional increases in exposure of orally
administered telcagepant may be a result of satu-
rable metabolism/efﬂux of telcagepant in the gut.
The relative bioavailabilty of telcagepant increases
with dose.
The oral formulation of telcagepant used in
the oral dose proportionality study (oral soft
elastic liquid ﬁlled capsule) was an early formu-
lation. However, this formulation demonstrated
bioequivalent exposure, with a dose adjustment,
with the anticipated tablet market formulation at
two separate doses (140 mg of the tablet compared
to 150 mg of the capsule and 280 mg of the tablet
compared to 300 mg of the capsule, unpublished
data). It is therefore expected that the conclusions
about dose proportionality would apply to the
anticipated market formulation.
In both studies, telcagepant was generally
well tolerated in healthy male and female subjects
when given as single oral doses, ranging from 50
to 600 mg, and single IV doses, ranging from 5
to 250 mg. This is in agreement with data from
a clinical trial looking at the efﬁcacy and toler-
ability of single oral doses of telcagepant up to
600 mg in migraine patients [8]. The long term
safety and tolerability proﬁle of telcagepant
in migraine patients is the subject of ongoing
studies.
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In summary, telcagepant is generally well tolerated
in young, healthy male and female subjects and
exhibits a pharmacokinetic proﬁle suitable for the
acute treatment of migraine. The pharmacokinet-
ics of telcagepant after an oral dose were observed
to be non-linear with greater than dose propor-
tional increases in exposure. When administered
IV, the pharmacokinetics were approximately dose
proportional.
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